Ira Oliff, MD
Hematology & Oncology · Skokie, ILNPI 1336138726
Payments from drug & device makers
Across 520 payments — averaging $3364.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$667K
- Amgen$202K
- Pfizer$198K
- Daiichi Sankyo Inc.$167K
- Incyte Corporation$79K
- Bristol Myers Squibb$70K
- plus $366K from 33 others
Across 2 payments — averaging $408.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$817
What the payments were for
- Food & beverage$1,21285%
- Education$21015%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 86 | $666,990 |
| Amgen | 22 | $202,344 |
| Pfizer | 53 | $198,004 |
| Daiichi Sankyo Inc. | 162 | $167,150 |
| Incyte Corporation | 36 | $79,290 |
| Bristol Myers Squibb | 12 | $69,859 |
| E.r. Squibb & Sons, L.L.C. | 9 | $66,614 |
| Biontech SE | 37 | $62,567 |
| Morphosys AG | 10 | $50,911 |
| Helsinn Healthcare SA | 9 | $35,900 |
| Regeneron | 7 | $25,021 |
| Eli Lilly | 3 | $21,390 |
| Astrazeneca UK Limited | 2 | $19,481 |
| Bioverativ Therapeutics Inc. | 1 | $11,000 |
| Puma Biotechnology, Inc. | 1 | $10,570 |
| Sanofi US Services Inc. | 6 | $9,861 |
| GSK | 9 | $9,749 |
| Eisai Inc. | 4 | $8,527 |
| Radius Health, Inc. | 2 | $6,094 |
| Dova Pharmaceuticals | 1 | $6,000 |
| AstraZeneca | 6 | $5,930 |
| Genentech, Inc. | 1 | $5,000 |
| Sobi, Inc | 3 | $4,023 |
| EMD Serono, Inc. | 2 | $3,289 |
| Pharmacyclics LLC, An Abbvie Company | 10 | $2,000 |
| Mirati Therapeutics, Inc. | 1 | $1,000 |
| Johnson & Johnson | 6 | $240 |
| Gilead | 5 | $161 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $69 |
| Novartis | 2 | $41 |
| Springworks Therapeutics, Inc. | 1 | $38 |
| Pharmaessentia USA Corporation | 1 | $32 |
| Genentech USA, Inc. | 1 | $30 |
| Bio Products Laboratory USA, Inc. | 2 | $28 |
| Novo Nordisk | 1 | $25 |
| Sanofi | 1 | $22 |
| Biocon Biologics Inc | 1 | $22 |
| Fresenius Kabi USA, LLC | 1 | $21 |
| Clovis Oncology, Inc. | 1 | $1 |
How this compares
$1,749,293 in reported general payments places this provider in the 90th percentile of 580 hematology & oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 32 | $628,902 |
| BrukinsaZanubrutinib | 23 | $305,125 |
| XtandiEnzalutamide | 21 | $301,520 |
| ImbruvicaIbrutinib | 13 | $211,277 |
| JakafiRuxolitinib Phosphate | 12 | $210,876 |
| ErleadaApalutamide | 13 | $186,485 |
| LumakrasSotorasib | 13 | $157,738 |
| Everolimus | 12 | $154,144 |
| HyqviaIgg/Hyaluronidase,recombinant | 13 | $92,808 |
| Gefitinib | 12 | $80,710 |
| Abiraterone Acetate | 50 | $71,256 |
| EliquisApixaban | 29 | $24,932 |
| Imatinib Mesylate | 26 | $16,726 |
| Megestrol Acetate | 24 | $2,905 |
| Anastrozole | 84 | $1,207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $69,859 | $628,90232 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $2,000 | $211,27713 claims |
| Incyte CorporationJakafi | $79,290 | $210,87612 claims |
| Johnson & JohnsonErleada | $240 | $186,48513 claims |
| AmgenLumakras | $202,344 | $157,73813 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Hyqvia | $69 | $92,80813 claims |
| PfizerEliquis | $198,004 | $24,93229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 580 hematology & oncology providers in Illinois.
Other hematology & oncology in Skokie
- Richard SchilskyBurr Ridge$87.1M
- Edwin PosadasBurr Ridge$70.9M
- Oana DanciuChicago$23.2M
- Shuo MaChicago$20.5M
- Olwen HahnChicago$11.9M
- Christine BestvinaChicago$11.3M
- Russell SzmulewitzChicago$9.8M
- Randy SweisChicago$9.4M
- Hedy KindlerChicago$8.6M
- Reem KarmaliChicago$7.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.